You can buy or sell Genmab and other stocks, options, ETFs, and crypto commission-free!
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Read More Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. GMXAY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
Copenhagen, Capital Region
52 Week High
52 Week Low
Simply Wall StMar 14
Investors Who Bought Genmab (CPH:GEN) Shares Five Years Ago Are Now Up 367%
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality companies can see their share prices grow by huge amounts. Don’t believe it? Then look at the Genmab A/S (CPH:GEN) share price. It’s 367% higher than it was five years ago. This just goes to show the value creation that some businesses can achieve. It’s also up 17% in about a month. This could be related to the recent financial results that were recently released – you could check the most recent d...
PR NewswireMar 12
Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
RARITAN, N.J., March 12, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The sBLA, based upon data from the Phase 3 ...
Simply Wall StMar 4